INCYTE CORP
Close on Oct 19, 2026
- Market cap
- $23.58B
- P/E (TTM)
- 14.4
- Dividend yield
- –
About Incyte
Services-Commercial Physical & Biological Research, SIC 8731
Incyte is a biopharmaceutical company that discovers, develops, and commercializes therapeutics across hematology, oncology, and inflammation and autoimmunity. Its approved portfolio includes treatments such as Jakafi, Iclusig, Monjuvi, and Niktimvo for hematologic conditions, Pemazyre and Zynyz for oncology indications, and Opzelura cream for inflammatory dermatological conditions. The company distributes its medicines to specialty, retail, and hospital pharmacies, specialty distributors, and pharmaceutical wholesalers.
The company operates globally, commercializing six compounds in the United States, three in Europe, and one in Japan. Its global headquarters is located in Wilmington, Delaware, alongside regional headquarters in Morges, Switzerland; Tokyo, Japan; and Montreal, Canada, in addition to multiple offices across Europe.
Summary of the business section of Incyte's latest annual report, written by StockData.
Company profile
Company
- Legal name
- INCYTE CORP
- Founded
- 2001
- Headquarters
- Wilmington, DE
- Address
- 1801 Augustine Cut-Off 19803
- Phone
- (302) 498-6700
- Website
- www.incyte.com
- Employees
- 2,844, Dec 31, 2025
- Industry
- Services-Commercial Physical & Biological Research
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Philadelphia, Pennsylvania
Stock & identifiers
- Ticker
- INCY
- Exchange
- Nasdaq
- IPO date
- Nov 4, 1993
- Shares outstanding
- 203M, Jul 21, 2026
- Public float
- $11.20B, Jun 30, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 2-for-1, Sep 1, 2000; 2-for-1, Nov 10, 1997
- SEC CIK
- 879169
- CUSIP
- 45337C102
- ISIN
- US45337C1027
- LEI
- 549300Z4WN6JVZ3T4680
- EIN
- 94-3136539
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| William Meury | Chief Executive Officer, Director | 183,129 |
| David H. Gardner | EVP, Chief Strategy Officer | 15,904 |
| Pablo J. Cagnoni | President, Global Head of R&D | 186,157 |
| Ramitpal K. Basi | EVP, Human Resources | 10,993 |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 63,648 |
| Lee Heeson | EVP, Head of Incyte Intl | 38,041 |
| Michael James Morrissey | EVP, Head of Tech. Operations | 34,065 |
| Thomas Tray | Principal Accounting Officer | 23,098 |
| Richard A. Hoffman | EVP & General Counsel | 16,861 |
| Steven H. Stein | CMO & Head of Late-Stage Dev. | 30,916 |
| Mohamed Khairie Issa | EVP, Head of U.S. Commercial | 63,940 |
| Suketu Upadhyay | EVP & Chief Financial Officer | 26,343 |
| Matteo Trotta | EVP, GM, Dermatology US | 14,882 |
| Sheila A. Denton | EVP & General Counsel | 26,569 |
| Vijay K. Iyengar | EVP, GMAPPS | 40,540 |
| Barry P. Flannelly | EVP & General Manager US | 35,149 |
| Paula J. Swain | EVP, Human Resources | 106,482 |
| Christiana Stamoulis | EVP & Chief Financial Officer | 125,759 |
| Edmund Harrigan | Director | 23,019 |
| Bros. Advisors (GP) LLC Baker | Director | 28,497,742 |
| Bros. Advisors Lp Baker | Director | 3,146,864 |
| 667, L.P. | Director | 3,132,639 |
| Brothers Life Sciences LP Baker | Director | 28,502,181 |
| Felix Baker | Director | 28,517,943 |
| Julian Baker | Director | 33,757,526 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Mr.Hoppenot | $6.38M | $23.38M | $6.33M | $114 | $120 |
| FY2025 Mr.Meury | $32.09M | $54.71M | $6.33M | $114 | $120 |
| FY2024 Herve Hoppenot | $17.46M | $25.23M | $5.91M | $79 | $91 |
| FY2024 Mr.Hoppenot | $17.46M | $25.23M | $5.91M | $79 | $91 |
| FY2024 Mr.Meury | $0 | $0 | $5.91M | $79 | $91 |
| FY2023 Herve Hoppenot | $16.66M | $7.84M | $7.84M | $72 | $92 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 2,844 employees, representing an increase of approximately 9% over our 2,617 employees as of the end of the prior year.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jun 1, 2016 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Mar 28, 2003 | Name change | Name changed from INCYTE INC to INCYTE CORP |
| Feb 25, 2003 | Name change | Name changed from INCYTE GENOMICS INC to INCYTE INC |
| Apr 18, 2000 | Name change | Name changed from INCYTE PHARMACEUTICALS INC to INCYTE GENOMICS INC |